Today: 21 May 2026
Ondas Holdings (ONDS) stock: Why shares jumped Friday and what traders are watching next
4 January 2026
2 mins read

Ondas Holdings (ONDS) stock: Why shares jumped Friday and what traders are watching next

NEW YORK, January 3, 2026, 18:00 ET — Market closed

  • Ondas Holdings shares closed up 12.9% on Friday at $11.02, with heavy volume.
  • The company said it plans to change its name to Ondas Inc. and has moved its corporate headquarters to West Palm Beach, Florida.
  • A separate filing showed a subsidiary extended note maturities to Jan. 15, while a director filed a Form 144 tied to a proposed share sale.

Ondas Holdings Inc. shares closed up 12.9% on Friday at $11.02, as investors digested a cluster of corporate updates and filings. Trading volume topped 136 million shares, according to Nasdaq data.

The move matters now because Ondas is reshaping its public-company profile at the same time its financing timeline is back in focus. The company operates in defense, security and industrial markets through autonomous systems and private wireless networking, and the latest disclosures give traders fresh signposts to track into January.

Friday’s advance left the stock near its 52-week high of $11.70, after trading between $9.91 and $11.06 in the session, according to Nasdaq and Yahoo Finance quote data. That kind of range is typical of a high-volatility small-cap name, and it can amplify moves around filings.

Ondas said it plans to change its corporate name to Ondas Inc., and that the name change is expected to take effect in the first quarter of 2026. The company also said it has relocated its corporate headquarters to West Palm Beach, Florida, and that the changes are not expected to disrupt operations or customer programs.

“Renaming the Company to Ondas Inc. will better align our corporate identity with the operating platform we have built,” Eric Brock, chairman and CEO, said in the statement. SEC filing

In the same release, Ondas said the relocation is intended to improve access to senior talent, strategic partners and institutional capital, while positioning the business in what it called an expanding defense and technology ecosystem in Florida. The company’s prior corporate address had been in Boston, according to the filing.

Separately, a current report filed Friday said Ondas Networks Inc., a subsidiary, signed a letter agreement amending the maturity date of certain notes to Jan. 15, 2026. The filing listed financings totaling about $8.0 million across multiple notes.

A Form 144 filed Friday showed director Ron Stern disclosed a proposed sale of up to 100,000 shares. A Form 144 is a notice filed under SEC Rule 144, which sets conditions for selling restricted or “control” shares; it does not guarantee a sale will occur. Form 144

Another filing, a Form 3, showed Robert Patrick Huston, listed as COO, general counsel and secretary, reported 100,000 restricted stock units and 100,000 stock options, among other items. Form 3 is an initial beneficial-ownership disclosure for certain insiders.

Before the next session, investors will be watching for any follow-through on the note maturity extension as Jan. 15 approaches, including any refinancing or restructuring steps disclosed in additional filings. The company has not laid out a detailed timeline beyond the January maturity date in the filing.

Traders will also look for the next earnings-date confirmation. Ondas’ investor-relations calendar currently shows no upcoming events scheduled, leaving the next catalyst dependent on company updates or third-party calendar estimates.

Technically, the stock is pressing its 52-week high near $11.70; a break above that level would put the focus on whether volume can stay elevated. On the downside, traders often watch the prior close around $9.76 and Friday’s intraday low near $9.91 as nearby reference points after a sharp single-day move.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
U.S. strikes Venezuela: What it could mean for BP, Shell and UK oil stocks on Monday
Previous Story

U.S. strikes Venezuela: What it could mean for BP, Shell and UK oil stocks on Monday

AAOI stock jumps 14% to start 2026 as Applied Optoelectronics rides AI data-center demand
Next Story

AAOI stock jumps 14% to start 2026 as Applied Optoelectronics rides AI data-center demand

Go toTop